Wolverine Trading
SNDX icon

Wolverine Trading’s Syndax Pharmaceuticals SNDX Stock Holding History

Wolverine Trading’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-13,286
Closed -$274K – 5342
2024
Q2 		$273K Buy
+13,286
New +$278K ﹤0.01% 3500

Other funds holding SNDX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Wolverine Trading's SNDX Position: Q3 2024 in Review

Wolverine Trading sold out of Syndax Pharmaceuticals (SNDX) in Q3 2024, closing a stake of 13,286 shares — an estimated $274K sold.

Wolverine Trading first reported a position in SNDX in Q2 2024 and held it in 1 quarter. The position peaked at $273K in Q2 2024. 210 funds tracked by Wall St. Rank hold SNDX as of Q3 2024.

  • Wolverine Trading reported no remaining Syndax Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Wolverine Trading sold 13,286 Syndax Pharmaceuticals shares in Q3 2024, an estimated $274K.
  • Wolverine Trading first reported a position in Syndax Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Wolverine Trading's Syndax Pharmaceuticals position peaked at $273K in Q2 2024.
  • 210 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2024.

Based on Wolverine Trading's 13F filing for Q3 2024, filed 14 Nov 2024.